The company intends to increase its specialty drug portfolio in its core areas ... The company’s Halol plant, receiving an import alert from the USFDA earlier in December, remains a challenge for Sun.
Shares of Sun Pharmaceutical Industries Ltd. inched down 0.64% to 951.50 Indian rupees Wednesday, on what proved to be an all ...
Sun Pharmaceutical Industries Ltd. shares inched up 0.36% to 957.60 Indian rupees Tuesday, on what proved to be an all-around ...
Sun Pharma's acquisition of Concert adds a complementary ... trials and is expected by the company to be filed with the US FDA in 1HCY23. “Given the unmet medical need and a strong efficacy ...
Sun Pharmaceutical ... by the US FDA. Pre-tax NPV of Rs 64 per share for Deuruxolitinib Sun’s competitive positioning is expected to be strong. Jefferies expects Sun Pharma to leverage its ...
Lupin, Sun Pharma share price: Wild swings in the Indian share market come in the backdrop of sharp falls in the global markets owing to weakness in the banking space, after the collapse of US-based ...
Brokerage firm Jefferies has termed Sun Pharmaceuticals as its top pick in the Indian pharma sector, while maintaining its Buy call on the back of the company’s specialty strategy and its strong India ...
Pharmaceutical industry stakeholders urged the US Food and Drug Administration (FDA) to better align its investigational new drug application (IND) annual reporting proposal with the International ...
FDA approval of Pfizer nasal spray migraine drug Zavzpret last week means a $475 million payday for Royalty Pharma. The payment stems from a financing deal Pfizer inherited when it acquired rights ...
Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated Jun 05, 2018, titled "Sun Pharma receives prestigious ... Proceedings Of National Company Law ...
